Clinical and biochemical status of patients with ulcerative collitis
https://doi.org/10.20340/vmi-rvz.2022.5.CLIN.7
Abstract
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), are chronic inflammatory conditions of the gastrointestinal tract characterized by a relapsing and remitting course. Aim - to analyze clinical data and the most significant hematological and biochemical blood parameters used for diagnosis in patients with ulcerative colitis. Materials and methods. Between 2020 and 2021 examined 50 patients with the diagnosis "Ulcerative colitis" living in the Samara region. The diagnosis of ulcerative colitis was confirmed by a combination of clinical, radiological, endoscopic, and histopathological criteria generally accepted for inflammatory bowel diseases. A hematological blood test was performed on an automatic hematological analyzer Sysmex KX-21N, Japan, and a biochemical blood test was performed on an automatic biochemical analyzer Hitachi 902, Japan. Results. In the biochemical analysis of blood, an increase in the content of C-reactive protein in the blood is expected in 64% of patients. In 40% of patients, the concentration of total protein and electrolytes decreases. An increase in glucose levels was revealed in 44% of patients, in 10% of cases, a decrease in creatinine concentration, an increase in the activity of ALAT and ASAT was noted in 6 and 4% of cases, respectively. Reduced urea levels are noted in 6% of patients. Conclusion. As a result of the study, the data necessary for the diagnosis and monitoring of the effectiveness of the treatment of ulcerative colitis were obtained.
About the Authors
Yu. A. Khalitova
Samara State Medical University
Russian Federation
Competing Interests:
Russian Federation
Samara.
Competing Interests:
The authors declare no competing interests.
Yu. V. Myakisheva
Samara State Medical University
Russian Federation
Competing Interests:
Russian Federation
Samara.
Competing Interests:
The authors declare no competing interests.
S. E. Katorkin
Samara State Medical University
Russian Federation
Competing Interests:
Russian Federation
Samara.
Competing Interests:
The authors declare no competing interests.
P. S. Andreev
Samara State Medical University
Russian Federation
Competing Interests:
Russian Federation
Samara.
Competing Interests:
The authors declare no competing interests.
D. S. Gromova
Samara State Medical University
Russian Federation
Competing Interests:
Russian Federation
Samara.
Competing Interests:
The authors declare no competing interests.
References
1. Ivashkin V.T., Sheptulin A.A., Mayev I.V., Baranskaya Y.K., Trukhmanov A.S., Lapina T.L., Burkov S.G., Kalinin A.V., Tkachev A.V. Diagnostics and treatment of peptic ulcer: clinical guidelines of the Russian gastroenterological Association. Russian Journal of Gastroenterology, Hepatology, Colo-proctology. 2016;26(6):40-54. (in Russ). https://doi.org/10.22416/1382-4376-2016-26-6-40-54
2. Suvorova G.N., Myakisheva YU.V., Katorkin S.E., Andreev P.S., Davydova O.E., Lyamin A.V., Kruglov E.E., Suhachev P.A. Histological picture and microbial landscape in ulcerative colitis. VNMT. 2018;4 (in Russ).
3. Myakisheva YU.V., Kolesova T.A., Halitova YU.A. Molecular genetic mechanisms of inflammatory bowel diseases and their biochemical markers. Molecular medicine. 2020;18 (6):19-25 (in Russ). https://doi.org/10.29296/24999490-2020-06-03
4. Matowicka-Karna J. Markers of inflammation, activation of blood platelets and coagulation disorders in inflammatory bowel diseases. Postepy Hig Med Dosw (Online). 2016 Apr 13;70:305-12.
5. Markova A.A., Kashkina E.I. Analysis of laboratory parameters in patients with non-specific ulcerative colitis. Bulletin of medical Internet conferences. 2014;1000 ID: 2014-08-8-A-4084 (in Russ).
6. Filmann N, Rey J, Schneeweiss S, Ardizzone S, Bager P, Bergamaschi G, Koutroubakis I, Lindgren S, Morena Fde L, Moum B, Vavricka SR, Schroder O, Herrmann E, Blumenstein I. Prevalence of anemia in inflammatory bowel diseases in european countries: a systematic review and individual patient data meta-analysis. Inflamm Bowel Dis. 2014 May;20(5):936-45. https://doi.org/10.1097/01.MIB.0000442728.74340.fd
7. Markova A. A., Kashkina E. I. Modern methods of diagnosis and assessment of the severity of ulcerative colitis. Bulletin of Russian universities. Maths. 2012;3 (in Russ).
8. Soubieres A.A., Poullis A. Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease. World J Gastrointest Pharmacol Ther. 2016;7(1):41-50. https://doi.org/10.4292/wjgpt.v7.i1.41
9. Silverberg M. S., Satsangi J., Ahmad T. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. The Canadian Journal of Gastroenterology. 2005;19:5A-36A.
10. Truelove S.C., Witts LJ Cortisone in ulcerative colitis; final report on a therapeutic trial. Br. Med. J. 1955;2:1041-8. https://doi.org/10.1136/bmj.2.4947.1041
11. Mack DR, Saul B, Boyle B, Griffiths A, Sauer C, Markowitz J, LeLeiko N, Keljo D, Rosh JR, Baker SS, Steiner S, Heyman MB, Patel AS, Baldassano R, Noe J, Rufo P, Kugathasan S, Walters T, Marquis A, Thomas SM, Denson L, Hyams J; PROTECT STUDY GROUP. Analysis of Using the Total White Blood Cell Count to Define Severe New-onset Ulcerative Colitis in Children. J Pediatr Gastroenterol Nutr. 2020 Sep;71(3):354-360.
12. Adams SM, Bornemann PH. Ulcerative colitis. Am Fam Physician. 2013 May 15;87(10):699-705; Chaubal A, Pandey V, Choksi D, Poddar P, Ingle M, Phadke A, Sawant P. Anemia in patients with ulcerative colitis in remission: A study from western India. Indian J Gastroenterol. 2017 Sep;36(5):361-365.
13. Pёrez de Arce E, Sedano R, Quera R. Biomarcadores en enfermedad inflamatoria intestinal: sabe como utilizarlos? [Biomarkers in inflammatory bowel disease]. Rev Med Chil. 2020 Mar;148(3):362-370.
14. Cioffi M, Rosa AD, Serao R, Picone I, Vietri MT. Laboratory markers in ulcerative colitis: Current insights and future advances. World J Gastrointest Pathophysiol. 2015;6(1):13-22. https://doi.org/10.4291/wjgp.v6.i1.13
15. Matson J., Ramamoorthy S., Lopez N.E. The Role of Biomarkers in Surgery for Ulcerative Colitis: A Review. J. Clin. Med. 2021;10: 3362. https://doi.org/10.3390/jcm10153362
16. Maconi G, Furfaro F, Sciurti R, Bezzio C, Ardizzone S, de Franchis R. Glucose intolerance and diabetes mellitus in ulcerative colitis: pathogenetic and therapeutic implications. World J Gastroenterol. 2014 Apr 7;20(13):3507-15.
17. Sidoroff M, Karikoski R, Raivio T, Savilahti E, Kolho KL. High-sensitivity C-reactive protein in paediatric inflammatory bowel disease. World J Gastroenterol. 2010;16(23):2901-2906. https://doi.org/10.3748/wjg.v16.i23.2901
18. Oraig A Solem, Edward V Loftus, William J Tremaine, William S Harmsen, Alan R Zinsmeister, William J Sandborn. Correlation of C-Reactive Protein With Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2005;11(8):707-712.
19. Hawker PC, McKay JS, Turnberg LA. Electrolyte transport across colonic mucosa from patients with inflammatory bowel disease. Gastroenterology. 1980 Sep;79(3):508-11.
20. Arivarasu N. Anbazhagan, Shubha Priyamvada, Waddah A. Alrefai & Pradeep K. Dudeja (2018) Pathophysiology of IBD associated diarrhea, Tissue Barriers, 6:2. https://doi.org/10.1080/21688370.2018.1463897
Review
For citations:
Khalitova Yu.A., Myakisheva Yu.V., Katorkin S.E., Andreev P.S., Gromova D.S. Clinical and biochemical status of patients with ulcerative collitis. Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH). 2022;(5):66-73. (In Russ.) https://doi.org/10.20340/vmi-rvz.2022.5.CLIN.7
Views:
415
Email this article 